NVO Jan 2024 80.000 call
| Previous close | 22.27 |
| Open | 22.30 |
| Bid | 20.20 |
| Ask | 22.60 |
| Strike | 80.00 |
| Expiry date | 2024-01-19 |
| Day's range | 22.20 - 22.30 |
| Contract range | N/A |
| Volume | |
| Open interest | 832 |
GlobeNewswireNovo Nordisk A/S - share repurchase programme
Bagsværd, Denmark, 04 December 2023 – On 6 November 2023, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 30 billion to be executed during a 12-month period beginning 1 February 2023. Under the programm
ZacksPfizer (PFE) Stock Down 5% as Obesity Drug Fails in Phase II
The failure of the phase IIb study on danuglipron is a significant blow to Pfizer's (PFE) efforts to take a share of the growing market of GLP-1 drugs for treating obesity.
Motley Fool3 No-Brainer Growth Stocks to Buy in December
Three Motley Fool contributors believe they've identified such exceptions. Here's why they think Eli Lilly (NYSE: LLY), Novo Nordisk (NYSE: NVO), and Vertex Pharmaceuticals (NASDAQ: VRTX) are no-brainer growth stocks to buy in December. David Jagielski (Eli Lilly): Eli Lilly is becoming a beast in the healthcare industry.
